


In the Claims:

Please amend the Claims as follows (the changes in these Claims are shown with ~~strikethrough~~ for deleted matter and underlines for added matter). A complete listing of the claims proper claim identifiers is set forth below.

1. **(Currently Amended)** A method for enhancing the bioavailability of ~~an orally administered therapeutically active compound of the formula (I)~~



ospemifene or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, ~~an ester thereof or a metabolite thereof selected from the group consisting of TORE VI (4-hydroxy(deaminohydroxy)toremifene), TORE VII (4,4'-dihydroxy(deaminohydroxy)toremifene), TORE XVIII ((deaminocarboxy)toremifene), TORE VIII (4-hydroxy(deaminocarboxy)toremifene) and TORE XIII (toremifene monophenol), wherein said compound is administered orally to the an individual in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids, being taken shortly before, during or shortly after administering the compound to enhance bioavailability of the compound.~~

2. **(Currently Amended)** The method according to claim 1 wherein ~~compound (I) the ospemifene~~ is ospemifene free base.

3. **(Original)** The method according to claim 1, wherein the compound is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake.

4. (**Previously Presented**) The method according to claim 3 wherein the compound is administered within one hour after the food intake was started.

5. (**Original**) The method according to claim 4 wherein the compound is administered at a time point which is no later than 0.5 hour after starting the food intake.


6. (**Canceled**)

7. (**Currently Amended**) The method according to claim 1 wherein the compound is used for treatment of osteoporosis and the compound is administered to a patient in need of treatment for osteoporosis.

8. (**Currently Amended**) The method according to claim 1 wherein the compound is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy and the compound is administered to a patient in need of treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy.

9. (**Original**) The method according to claim 8 wherein the symptoms related to atrophy are urinary symptoms or vaginal symptoms.


10. (**Currently Amended**) The method according to claim 7, wherein the therapeutically active compound is the Z-isomer of ~~a compound of formula (I)~~



ospemifene, or pharmaceutically acceptable salt thereof, and wherein the dosage amount is from 30 to 90 mg/day.

11. (**Previously Presented**) The method according to claim 10, wherein the dosage amount is 60 mg.

12. (**Previously Presented**) The method according to claim 8, wherein the therapeutically active compound is the Z-isomer of ~~a compound of formula (I)~~



ospemifene, or pharmaceutically acceptable salt thereof, and wherein the dosage amount is from 30 to 90 mg/day.

13. (**Previously Presented**) The method according to claim 12, wherein the dosage amount is 60 mg.

14. (**New**) The method according to claim 2, wherein the compound is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy and the compound is administered to a patient in need of treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy.

15. (**New**) The method according to claim 14, wherein the therapeutically active compound is the Z-isomer of ospemifene, or a pharmaceutically acceptable salt thereof, and wherein the dosage amount is from 30 to 90 mg/day.

16. (**New**) The method according to claim 15, wherein the dosage amount is 60 mg.

17. (**New**) The method according to claim 2, wherein the compound is used for treatment of osteoporosis and the compound is administered to a patient in need of treatment for osteoporosis.

18. (**New**) The method according to claim 17, wherein the therapeutically active compound is the Z-isomer of ospemifene, or a pharmaceutically acceptable salt thereof, and wherein the dosage amount is from 30 to 90 mg/day.

19. (**New**) The method according to claim 18, wherein the dosage amount is 60 mg.